Online Extras

New faces among the Pharma Industry rise the ranks

There is a lot of buzz about “the cloud.” Formally known as cloud computing, the cloud relies on sharing of Information Technology (IT) resources.

New faces among the Pharma Industry rise the ranks.

Challenging. Time-consuming. Expensive. Do words like these spring to mind when you contemplate the patient recruitment process for your clinical trials?

Make sure your perspective is heard, and get valuable insights and data for your TMF improvement initiatives

Graphics and data regarding the current state of the Clinical Trials industry.

New faces among the Pharma Industry rise the ranks.

The application of personal device technology in the health care space continues to evolve, fed by the development of health-related consumer products and services by segments of industry traditionally not focused on health

As clinical trials continue to grow in complexity, tolerance for the growing variance between forecasted and actual clinical trial costs is shrinking.

New faces among the Pharma Industry rise the ranks.

The emergence of risk-based monitoring (RbM) is creating a revolution in the way biopharmaceutical sponsors and CROs manage clinical trial quality.

Palatin Technologies is a biotech company focused on developing targeted, receptor-specific, peptide therapeutics for the treatment of diseases with significant, unmet medical needs and commercial potential.

New faces among the Pharma Industry rise the ranks.

Clinical trial site engagement has been advocated as a critical component relating to a study’s performance and success, however, a minimum amount of data supports this connection.

 Sentiment analysis can give health care organizations a competitive edge in understanding what customers think about their healthcare experience, to help reduce costs and improve care service and to lead to new clinical research and treatments. In addition, it taps into a new channel of pharmacovigilance input information that can enable Marketing Authorization Holders to keep abreast of opinions on the safety of their products in real time.

Many years before the FDA offered its eSource Guidance in September 2013, Sirion Therapeutics launched its first two pivotal Phase III studies using entirely electronic source data collection.

The current regulatory environment of a particular country plays an important role in the geographic selection. For India, it is very relevant because of problems in clinical trials approval and conduct issues during last few years.

IntroductionAfter decades of promise, we have begun to realize the fruit of “-omics” technology. Recent advances in proteomics, genomics and metabolomics have enabled us to understand the molecular basis of disease at both the diagnostic and treatment levels. Equally important, a growing suite of biomarkers now provides predictive value for diagnosis, disease progression and cure/remission.

In early January, Novartis selected Qualcomm Life as a global digital health collaborator for its Trials of The Future program. That program is designed to leverage healthcare technology to improve the experience of clinical trial participants and patients using Novartis products.

The developed markets of North America and Europe together saw approximately 81% of the Phase I trial share in 2013 which is a 6% increase from 2012. Trials

The need for innovation in clinical trials has sparked significant interest from a variety of new enterprises including technology, analytics, subject enrollment/engagement/retention, EDC, risk-based monitoring, and many mor

The drive to accelerate drug development has highlighted the benefit in using RTSM systems within early phase cohort trials.

It is well documented that lengthy start-up at individual trial sites related to contracting and committee reviews contributes significantly to delays.

This article is the first in a series of articles that will review the development and findings of the first scientific measurement of quality in clinical trials.

This guidance document will offer information about RbM strategies.

All signs indicate that 2015 should be another good year for contract research organizations (CROs).

As clinical games emerge as a new tool for diagnosing and treating cognitive health, it is important to understand how these tools work and the ways in which these tools are validated, as well as how to realize their full potential.

Celgene Corporation uses the PHT Corporation SitePad System and StudyWorks to collect patient-driven eData for OTEZLA (apremilast) tablets approved by the FDA in March 2014

The US FDA, in open meetings, stated the Thorough QT trial "must" be replaced.

A growing number of providers are adapting 21st century web-based and mobile tools to connect the corners, boost trial participation, and speed trial completion.